Pfeffer M, Swedberg K, Granger C, Held P, McMurray J, Michelson E, Olofsson B, Ostergren J, Yusuf S, Pocock S (2003). “Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme”. Lancet362 (9386): 759–66. doi:10.1016/S0140-6736(03)14282-1. PMID13678868.
Mizuno, K. (1992). “Hypotensive activity of TCV-116, a newly developed angiotensin II receptor antagonist, in spontaneously hypertensive rats.”. Life Sci.51 (20): PL183-187. doi:10.1016/0024-3205(92)90627-2. PMID1435062.
Pfeffer M, Swedberg K, Granger C, Held P, McMurray J, Michelson E, Olofsson B, Ostergren J, Yusuf S, Pocock S (2003). “Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme”. Lancet362 (9386): 759–66. doi:10.1016/S0140-6736(03)14282-1. PMID13678868.
Mizuno, K. (1992). “Hypotensive activity of TCV-116, a newly developed angiotensin II receptor antagonist, in spontaneously hypertensive rats.”. Life Sci.51 (20): PL183-187. doi:10.1016/0024-3205(92)90627-2. PMID1435062.
Ogihara, T. (Jul–Aug 1993). “Pilot study of a new angiotensin II receptor antagonist, TCV-116: effects of a single oral dose on blood pressure in patients with essential hypertension.”. Clin Ther.15 (4): 684–91. PMID8221818.